89

Spain has quietly recalibrated the rules of access.

With Royal Decree 90/2026, the Spanish National Health System has modernised how certain non-hospital medical products enter public financing. What was once governed by a 1996 framework is now aligned with contemporary principles of HTA discipline, economic scrutiny, and structured reimbursement governance. The reform applies specifically to defined categories of medical aids reimbursed under the outpatient pharmaceutical benefit. It does not extend to hospital-only devices, DRG-funded technologies, or digital health tools outside the listed annexes. Understanding this scope limitation is essential before assuming applicability.

This is not a cosmetic update. It is structural.

For MedTech and pharmaceutical companies, the message is clear:
Spain is now operating a selective, HTA-informed reimbursement access model for defined categories of medical aids.

Inclusion is no longer procedural. It is evidentiary.

Products must demonstrate:

• Clinical usefulness
• Comparative positioning
• Cost-effectiveness
• Budget impact sustainability
• EU price coherence

Pricing is determined centrally, with maximum industrial prices (PVL) and regulated margins, overseen through medicine-style governance mechanisms. Homogeneous groupings and lowest-price substitution rules introduce explicit reference-pricing dynamics, increasing pressure on undifferentiated products.

In practical terms:

• Access requires structured submission.
• Differentiation must be proven, not asserted.
• Economic modelling becomes foundational, not optional.

At the same time, the system creates opportunity.

The framework allows the structured inclusion of new suppliers and innovative products, with clear timelines and transparent administrative procedures. For companies prepared to engage with Spain through rigorous HTA-aligned evidence and disciplined pricing strategy, reimbursement access is navigable.

The strategic inflection point lies in classification.
If a product is deemed homogeneous, it will compete on price.
If it is demonstrably differentiated, it can compete on value.

Spain has not closed its doors.
It has professionalised them.

And in doing so, it has moved closer to the broader European trajectory where HTA logic shapes reimbursement access across both pharma and medtech markets.

The implication is simple:

Reimbursement access in Spain now requires strategic preparation, economic clarity, and disciplined positioning.

Those who adapt early will shape the reference points that follow.

Step 1 Confirm Regulatory and Structural Eligibility

Before considering pricing or reimbursement strategy, determine whether your product can legally and structurally enter the system. Final determination of eligibility and category assignment rests with the administration, not the applicant. Early informal validation of classification assumptions can prevent misaligned submissions, particularly for borderline or hybrid products.

Under Royal Decree 90/2026, eligibility is not assumed. It is defined.

Your product must:

• Belong to one of the recognised categories covered under the pharmaceutical benefit for non-hospitalised patients (wound care materials, drug administration devices, products for the collection of excreta or secretions, or protective/supportive devices for internal injuries or malformations).
• Hold a valid CE mark and comply fully with current EU regulatory requirements.
• Be industrially manufactured (custom or bespoke products fall outside scope).
• Require a prescription or formal dispensing order.
• Not be marketed directly to the general public.

Even if these conditions are met, financing is not automatic.
Inclusion requires a formal administrative decision following technical and economic evaluation.

At this stage, companies should also determine whether the product is likely to fall within an existing homogeneous grouping. This classification will shape the entire access strategy. Products deemed interchangeable will face lowest-price substitution rules. Products that can demonstrate meaningful differentiation may avoid commoditisation.

Eligibility is therefore both regulatory and strategic.

If the product does not meet the formal criteria, it cannot enter the system.
If it meets them but lacks differentiation, it may enter — but at reference price.

Understanding this distinction at the outset prevents misaligned submissions and unrealistic pricing expectations.

Step 2 Determine Your Classification and Positioning Before You Talk Price

Under Royal Decree 90/2026, your product’s classification determines how it is paid. Once a product is placed within a homogeneous grouping, reclassification is procedurally possible but practically difficult. Initial positioning, therefore, carries long-term consequences for pricing power and substitution exposure.

Before submitting anything, you must answer a difficult question:

Will the product be considered interchangeable with existing options?

If the answer is yes, it will fall into a homogeneous group.
That means:

• Lowest-price substitution rules apply.
• Pricing flexibility narrows.
• Commercial strategy becomes volume-driven.

If the product introduces a clinically meaningful distinction — improved outcomes, measurable safety advantage, superior usability, reduced complications, or system efficiencies — then you must position it as differentiated.

But differentiation is not a claim. It is a comparative argument.

You must be able to demonstrate:

• What is different,
• Why it matters clinically,
• And how that difference affects cost or outcomes.

This assessment should be made before price is proposed.
In Spain’s current system, classification precedes negotiation.

Misjudge classification, and the pricing discussion is over before it begins.

Step 3 Build a Structured, Evidence-Based Dossier

Spain now expects disciplined submissions. Financing decisions are informed by technical and economic evaluation. While the process does not constitute a full formal health technology assessment in the pharmaceutical sense, the analytical expectations mirror HTA discipline. Submissions that anticipate economic scrutiny perform better than those that rely solely on regulatory compliance.

Your dossier should therefore resemble a focused HTA file, including:

• Clear description of clinical utility and intended use
• Structured comparison with relevant alternatives
• Evidence supporting added benefit, where claimed
• Economic rationale (cost-offset logic or cost-effectiveness framing)
• Budget impact projection for the Spanish National Health System
• Proposed Maximum Industrial Price (PVL), with justification
• EU price benchmarking
• Volume forecasts and uptake assumptions
• Full regulatory documentation and conformity evidence

The economic component does not need to be academically complex.
It does need to be coherent.

Authorities will ask:

• Does this improve care?
• Does it replace or duplicate?
• What does it cost the system?
• How does it compare internationally?

A submission that answers these questions clearly stands a chance.
A submission that relies on marketing language does not.

Under this framework, reimbursement access in Spain is not rhetorical.
It is evidentiary.

Step 4 Navigate the Administrative and Technical Evaluation

Applications are submitted electronically to the
Dirección General de Cartera Común de Servicios del SNS y Farmacia.

Submission triggers two parallel processes:

1. Administrative validation
   The dossier is checked for completeness and formal compliance. Missing documentation can delay the clock before evaluation even begins.
2. Technical and economic assessment
   The authority reviews:
   • Clinical utility
   • Comparative positioning
   • Budget impact
   • Proposed pricing
   • EU price references
   • System sustainability

During this phase, requests for clarification or additional information are common. Responses must be precise and timely. Delayed or inconsistent answers weaken credibility and may affect the outcome. The evaluation phase establishes the administration’s perception of the applicant. Inconsistent economic logic, unsupported claims, or delayed responses may influence not only the current application but future submissions within the same product family.

The administration has up to six months to issue a decision. Silence is not approval; a formal resolution is required.

Strategically, this phase is not passive.
Companies should anticipate questions in advance, prepare scenario pricing responses, and ensure that economic assumptions are defensible.

The evaluation is not adversarial — but it is structured and disciplined.

Step 5 Pricing Resolution and Market Positioning

If financing is approved, pricing is determined centrally.

The Interministerial Commission on Medicines Pricing establishes the Maximum Industrial Price (PVL). This anchors the entire commercial structure.

Distribution and pharmacy margins are then applied in accordance with the regulatory framework. The product is assigned to a reimbursement grouping, which determines whether homogeneous substitution rules apply. EU price benchmarking is not mechanical but directional. Companies should assess how Spanish pricing may subsequently influence reference baskets in other Member States. Spain is not only influenced by Europe it also influences Europe.

Three realities follow approval:

• The proposed price is rarely accepted without scrutiny.
• International reference prices will influence the final decision.
• Classification within a homogeneous group may compress pricing latitude.

This stage may involve adjustment rather than negotiation in the traditional commercial sense. The system is rule-based, not discretionary.

Companies should therefore:

• Enter with a justified and defensible PVL,
• Understand how EU prices shape expectations,
• Model the financial impact of margin structures,
• Prepare for potential downward revision.

Approval secures access.
Final price determines viability.

The distinction matters. Companies should model net revenue on a regulated-margin basis before confirming PVL assumptions. Gross price is not the realised price.

Step 6 Manage Reimbursement as an Ongoing Obligation, Not a One-Time Approval

Securing inclusion under Royal Decree 90/2026 is not the end of the process. It marks the beginning of structured oversight.

Once financed, your product operates within a monitored reimbursement environment. Pricing, classification, and utilisation remain subject to review.

Companies must actively manage four dimensions:

Price Evolution and Review Cycles

The framework provides for periodic monitoring of prices and margins.

Authorities may:

• Reassess the Maximum Industrial Price (PVL),
• Adjust distribution and dispensing margins,
• Revisit group classification,
• Respond to the entry of lower-priced alternatives.

If competitors enter at lower prices, homogeneous group dynamics can trigger downward pressure. Pricing strategy must therefore anticipate competitive evolution, not just initial approval.

Homogeneous Group Exposure

If the product is placed within a homogeneous group, substitution rules apply.

This means:

• Pharmacies must dispense the lowest-priced option,
• New market entrants can reset the reference price,
• Market share becomes price-sensitive.

Differentiation must be continuously defensible. Evidence supporting clinical or functional distinction should not remain static. Post-market data can become strategically important.

Utilisation and Budget Controls

The administration retains authority to introduce:

• Prior authorisation requirements,
• Indication limitations,
• Spending caps,
• Risk-sharing or managed-entry conditions.

These tools are designed to preserve system sustainability. Companies should closely monitor utilisation patterns and budgetary impact, particularly if uptake exceeds projections. Strategic lifecycle management may include periodic reassessment of positioning, price defence strategies, and proactive engagement before formal review cycles.

Forecasts submitted during the application phase may be revisited.

Market Presence and Supply Responsibilities

Approval carries operational obligations:

• Authorities must be notified of market launch within one year.
• Supply continuity must be maintained.
• Shortages may trigger authorised substitution.

Failure to launch or maintain supply can undermine reimbursement status.

The Strategic Principle

Reimbursement in Spain is now rule-based and continuously supervised. Although pricing and inclusion are determined nationally, utilisation and procurement dynamics may vary across Autonomous Communities. Regional implementation patterns can influence real-world uptake and should be monitored accordingly.

Access requires preparation.
Sustainability requires vigilance.

Companies that treat approval as an endpoint risk erosion through price revision, substitution dynamics, or utilisation controls.

Companies that treat reimbursement as a managed lifecycle preserve both position and pricing integrity.

Under Royal Decree 90/2026, entry is structured.
So is survival.